

## ASX Release

### Appendix 4C – Q3 2026 Quarterly Cash Flow Report

27 October 2026 – Melbourne, Australia – Oneview Healthcare PLC (ASX:ONE) ("Oneview" or "the Company"), a global healthcare technology company, today released its Appendix 4C – Quarterly Cashflow report for the quarter ending 30 September 2026 (Q3 26) and provided an update on business activities.

#### Highlights

- **A record quarter for new customer adoption with six new customer logos added, including four customer agreements for initial Bedside Hub TV deployments.**
- **Cash balance at 30 September 2026 of €2.4 million (A\$3.9m) impacted by delayed customer receipt. Cash balance at 26 October 2026: €4.2 million (A\$6.7 million).**
- **Pro-forma cash balance at 26 October 2026: €8.6 million (A\$13.7 million), including Tranche 2 of the institutional placement.**

#### Sales and Customer Updates

##### *Epic Bedside Hub TV*

Oneview has signed agreements for initial Bedside Hub TV deployments at Albany Med Health System, Baptist Health, Jupiter Medical Center and Shannon Health. These first four customer agreements mark an important commercial milestone following Bedside Hub's launch in May 2026.

Bedside Hub provides healthcare-grade hardware and cloud-based device management to host Epic MyChart Bedside TV, creating an additional growth channel for Oneview among health systems using Epic as their electronic medical record system.

The initial customer group includes major regional and academic health systems, and an independent community hospital:

- **Albany Med Health System:** A New York-based academic health system with approximately 1,520 hospital beds across four hospitals, serving northeastern New York and western New England.
- **Baptist Health:** Serves Kentucky and southern Indiana, with more than 2,400 licensed beds across eight owned hospitals.
- **Jupiter Medical Center:** An independent, not-for-profit hospital in Florida with 340 licensed beds, serving Palm Beach County and the Treasure Coast.

- **Shannon Health:** A Texas-based regional healthcare system whose San Angelo medical centre has more than 600 licensed beds.

Together, these four customer organizations represent a combined footprint of almost 5,000 beds, providing a significant opportunity for expansion beyond the initial deployments. This figure reflects their broader bed capacity; the signed agreements cover initial deployments rather than their entire bed base. The market's response to the Company's bedside Hub offering has materially shortened the sales-cycle with two of these opportunities having progressed from first contact to signing in less than 3 months.

#### *Care Experience Platform*

Oneview has also secured two new customers for its Care Experience Platform:

- **Martin Luther King, Jr. Community Hospital:** A 131-bed, private, not-for-profit hospital serving South Los Angeles, California; and
- **Northeastern Vermont Regional Hospital,** a 25-bed critical access hospital serving Vermont's Northeast Kingdom.

Commercial momentum remains strong. In its Q2 Appendix 4C update, the Company indicated that it was targeting the addition of approximately three to four new Bedside Hub customers during the second half of 2026. Four new Bedside Hub customers have already been added since that target was provided, placing the Company ahead of its previous expectations. The Company has also added two new customers for its Care Experience Platform. With further opportunities progressing through the pipeline, alongside expansion opportunities within the existing customer base, the Company expects to finish the year with between 8 and 10 new customer logos.

#### *Product Updates*

During the quarter, Oneview moved several strategic product initiatives from development into deployment. The Company's redesigned patient user interface progressed from nearing completion in Q2 to its first customer deployment. Initial customer feedback was very positive, particularly regarding the improved user experience, visual design and responsiveness. The updated interface includes simpler navigation and home-screen design, redesigned meal ordering and patient service workflows, and new in-product feedback capabilities. A second deployment with a major US customer is underway, followed by a phased migration of existing customers during 2027.

Oneview also advanced the AI-powered Ovie Digital Care Assistant from pilot planning in Q2 towards customer deployment with a major US healthcare system. The customer's AI Governance process was initiated, preparation is underway for deployment to a customer environment in Q4, and the pilot project formally commences in November. The beta pilots are intended to validate the technology, user experience and operational workflows required before the products progress towards general availability.

The Company continued to strengthen the reliability and data capabilities underpinning its platform. Work during the quarter included software-component upgrades, enhanced device

and application monitoring, and the introduction of a standardised service-level indicator framework to measure user-impacting issues across deployed devices.

## Outlook

CEO James Fitter commented, "The third quarter marked a record quarter for new customer acquisition at Oneview, with six new customers secured across Bedside Hub and our Care Experience Platform. These wins broaden our customer base across academic, regional and specialist healthcare organisations and reflect the growing commercial momentum across the business.

Our first Bedside Hub customer wins represent an important milestone in establishing a new and potentially scalable revenue channel for Oneview. They validate the differentiation of our healthcare-grade hardware and cloud-based device management solution for Epic MyChart Bedside TV, while demonstrating the potential for a faster path to customer acquisition and deployment. Importantly, these initial agreements establish new relationships with healthcare organisations that provide meaningful opportunities for expansion beyond the initial deployment.

Our focus for the remainder of 2026 is to convert this momentum into further customer wins and deployments, while expanding our footprint within both new and existing customers."

Engagement between Oneview and one of the United States' ten largest health systems continues to advance following the inclusion of Oneview's products under an amendment to Baxter's National Care Communication Agreement with the health system's group purchasing organisation earlier this year.

## Q3 Cash Flow Report

Oneview's cash balance at 30 September 2026 was €2.4 million (A\$3.9m) compared to €7.2 million (A\$11.9m) at 30 June 2026. The cash balance at the end of September was negatively impacted by the delayed receipt of an annual customer renewal fee of US\$2.23 million (approximately €2.0m / A\$3.2m) that was due in the quarter but not received until 19 October 2026. The Company's cash balance at 26 October 2026 is €4.2 million (A\$6.7 million).

In March 2026, the Company completed a two-tranche institutional placement raising A\$19 million (approximately €11.4 million) in gross proceeds. Tranche 1 of the Placement, which raised A\$12 million (approximately €7.2 million), was settled on 24 March 2026. Tranche 2 of the Placement, which will raise a further A\$7.0 million (approximately €4.4 million) in gross proceeds, remains subject to shareholder approval. Settlement of Tranche 2 will occur following receipt of this approval, which the Company is seeking at its annual general meeting which is being held on 25 November 2026. On a pro forma basis, upon receipt of Tranche 2 of the institutional placement, the Company's cash balance at 26 October 2026 would have been approximately €8.6 million (A\$13.7 million).

The Company recorded a net operating cash outflow of €4.8 million (A\$7.6m) during the quarter, compared to an outflow of €2.2 million (A\$4.0m) in the corresponding period of 2025. The increase primarily reflects the timing of annual subscription receipts rather than any change

in customer retention, with all delayed renewals either received since quarter end or expected in the coming weeks.

Specifically, the higher cash outflow primarily reflects €2.1 million of lower receipts during the quarter. €1.3 million of this decrease relates to delayed payments for annual subscriptions from three contracted customers for their annual subscription charges this year, which they had paid by 30 September 2025. Payments from all three customers are expected in the coming weeks. The remainder of the reduction is attributable to receipts from one-off hardware sales made during the second quarter of 2025 which were not repeated during the second quarter of 2026.

Q4 and Q1 have historically been the Company's strongest cash-receipt quarters and have generally recorded the lowest net operating cash outflows, reflecting the billing and collection of several large annual customer renewals during these periods. This trend is expected to continue in the next two quarters, and we expect it will be complemented by the new Bedside Hub business detailed above.

Total costs in Q3 2026 were broadly in line with the corresponding period of 2025, with lower staff, product and operating costs offset by higher administration and corporate costs.

In accordance with ASX Listing Rule 4.7C, payments made to related parties and their associates are included in item 6.1 of the Appendix 4C. Payments to related parties of the entity and their associates in the quarter were comprised of directors' fees and salaries totalling €186,179 (A\$304,711).

**This announcement has been approved for release by the board of Oneview Healthcare plc.**

### **About Oneview Healthcare plc**

For healthcare systems who lead on exemplary care, Oneview Healthcare plc provides digital tools for patients, families and caregivers to improve the care experience. Unifying a facility's systems, content and services into one digital platform with dedicated devices at the point of care, Oneview helps deliver more control for patients and families, more time for care teams, and less complexity for executives and IT teams. Oneview is proud to partner with leading healthcare systems in the US, Australia, Ireland, the Middle East and Asia to unify the care experience, in over 80 hospitals.

Enquiries:

James Fitter, CEO

Darragh Lyons, CFO

Website : [www.oneviewhealthcare.com](http://www.oneviewhealthcare.com)

## Appendix 4C

### Quarterly cash flow report for entities subject to Listing Rule 4.7B

**Name of entity**

Oneview Healthcare PLC

**ABN**

610 611 768

**Quarter ended ("current quarter")**

30<sup>th</sup> September 2026

| Consolidated statement of cash flows |                                                       | Current quarter<br>€'000 | Year to date (9<br>months)<br>€'000 |
|--------------------------------------|-------------------------------------------------------|--------------------------|-------------------------------------|
| <b>1.</b>                            | <b>Cash flows from operating activities</b>           |                          |                                     |
| 1.1                                  | Receipts from customers                               | 594                      | 5,736                               |
| 1.2                                  | Payments for                                          |                          |                                     |
|                                      | (a) research and development                          | -                        | 595                                 |
|                                      | (b) product manufacturing and operating costs         | (883)                    | (2,521)                             |
|                                      | (c) advertising and marketing                         | (51)                     | (331)                               |
|                                      | (d) leased assets                                     | -                        | -                                   |
|                                      | (e) staff costs                                       | (2,688)                  | (8,414)                             |
|                                      | (f) administration and corporate costs                | (1,433)                  | (3,668)                             |
| 1.3                                  | Dividends received (see note 3)                       | -                        | -                                   |
| 1.4                                  | Interest received                                     | 12                       | 45                                  |
| 1.5                                  | Interest and other costs of finance paid              | -                        | -                                   |
| 1.6                                  | Income taxes (paid)/refunded                          | -                        | -                                   |
| 1.7                                  | Government grants and tax incentives                  | -                        | -                                   |
| 1.8                                  | Other (working capital movements)                     | (308)                    | (380)                               |
| <b>1.9</b>                           | <b>Net cash from / (used in) operating activities</b> | <b>(4,757)</b>           | <b>(8,938)</b>                      |

|            |                                                       |            |              |
|------------|-------------------------------------------------------|------------|--------------|
| <b>2.</b>  | <b>Cash flows from investing activities</b>           |            |              |
| 2.1        | Payments to acquire or for:                           |            |              |
|            | (a) entities                                          | -          | -            |
|            | (b) businesses                                        | -          | -            |
|            | (c) property, plant and equipment                     | (3)        | (138)        |
|            | (d) investments                                       | -          | -            |
|            | (e) intellectual property                             | -          | -            |
|            | (f) other non-current assets                          | -          | -            |
| 2.2        | Proceeds from disposal of:                            |            |              |
|            | (a) entities                                          | -          | -            |
|            | (b) businesses                                        | -          | -            |
|            | (c) property, plant and equipment                     | -          | -            |
|            | (d) investments                                       | -          | -            |
|            | (e) intellectual property                             | -          | -            |
|            | (f) other non-current assets                          | -          | -            |
| 2.3        | Cash flows from loans to other entities               | -          | -            |
| 2.4        | Dividends received (see note 3)                       | -          | -            |
| 2.5        | Other (provide details if material)                   | -          | -            |
| <b>2.6</b> | <b>Net cash from / (used in) investing activities</b> | <b>(3)</b> | <b>(138)</b> |

|             |                                                                                         |          |              |
|-------------|-----------------------------------------------------------------------------------------|----------|--------------|
| <b>3.</b>   | <b>Cash flows from financing activities</b>                                             |          |              |
| 3.1         | Proceeds from issues of equity securities (excluding convertible debt securities)       | -        | 7,411        |
| 3.2         | Proceeds from issue of convertible debt securities                                      | -        | -            |
| 3.3         | Proceeds from exercise of options                                                       | -        | -            |
| 3.4         | Transaction costs related to issues of equity securities or convertible debt securities | -        | (598)        |
| 3.5         | Proceeds from borrowings                                                                | -        | -            |
| 3.6         | Repayment of borrowings                                                                 | -        | -            |
| 3.7         | Transaction costs related to loans and borrowings                                       | -        | -            |
| 3.8         | Dividends paid                                                                          | -        | -            |
| 3.9         | Other (provide details if material)                                                     | -        | -            |
| <b>3.10</b> | <b>Net cash from / (used in) financing activities</b>                                   | <b>-</b> | <b>6,813</b> |

**Appendix 4C**

**Quarterly cash flow report for entities subject to Listing Rule 4.7B**

|            |                                                                              |              |              |
|------------|------------------------------------------------------------------------------|--------------|--------------|
| <b>4.</b>  | <b>Net increase / (decrease) in cash and cash equivalents for the period</b> |              |              |
| 4.1        | Cash and cash equivalents at beginning of period                             | 7,191        | 4,602        |
| 4.2        | Net cash from / (used in) operating activities (item 1.11 above)             | (4,757)      | (8,938)      |
| 4.3        | Net cash from / (used in) investing activities (item 2.6 above)              | (3)          | (138)        |
| 4.4        | Net cash from / (used in) financing activities (item 3.10 above)             | -            | 6,813        |
| 4.5        | Effect of movement in exchange rates on cash held                            | 5            | 97           |
| <b>4.6</b> | <b>Cash and cash equivalents at end of period</b>                            | <b>2,436</b> | <b>2,436</b> |

|            |                                                                                                                                                                             |                                  |                                   |
|------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------------------------------|
| <b>5.</b>  | <b>Reconciliation of cash and cash equivalents</b><br>at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts | <b>Current quarter<br/>€'000</b> | <b>Previous quarter<br/>€'000</b> |
| 5.1        | Bank balances                                                                                                                                                               | 2,436                            | 7,191                             |
| 5.2        | Call deposits                                                                                                                                                               | -                                | -                                 |
| 5.3        | Bank overdrafts                                                                                                                                                             | -                                | -                                 |
| 5.4        | Other (provide details)                                                                                                                                                     | -                                | -                                 |
| <b>5.5</b> | <b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>                                                                                            | <b>2,436</b>                     | <b>7,191</b>                      |

|                                                                                                                                                                 |                                                                                         |                                  |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|----------------------------------|
| <b>6.</b>                                                                                                                                                       | <b>Payments to related parties of the entity and their associates</b>                   | <b>Current quarter<br/>€'000</b> |
| 6.1                                                                                                                                                             | Aggregate amount of payments to related parties and their associates included in item 1 | 186                              |
| 6.2                                                                                                                                                             | Aggregate amount of payments to related parties and their associates included in item 2 | -                                |
| <i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i> |                                                                                         |                                  |

|                                                                                                                                                                                                                                                                                                                                                 |                                                       |                                              |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|----------------------------------------------|
| <b>7. Financing facilities</b><br><i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i><br><i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>                                                                                               | <b>Total facility amount at quarter end<br/>€'000</b> | <b>Amount drawn at quarter end<br/>€'000</b> |
| 7.1 Loan facilities                                                                                                                                                                                                                                                                                                                             | -                                                     | -                                            |
| 7.2 Credit standby arrangements                                                                                                                                                                                                                                                                                                                 | -                                                     | -                                            |
| 7.3 Other (please specify)                                                                                                                                                                                                                                                                                                                      | -                                                     | -                                            |
| 7.4 <b>Total financing facilities</b>                                                                                                                                                                                                                                                                                                           | -                                                     | -                                            |
| 7.5 <b>Unused financing facilities available at quarter end</b>                                                                                                                                                                                                                                                                                 |                                                       | -                                            |
| 7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well. |                                                       |                                              |

|                                                                                                                                                                                                                                                                                                                                                                                                                        |              |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|
| <b>8. Estimated cash available for future operating activities</b>                                                                                                                                                                                                                                                                                                                                                     | <b>€'000</b> |
| 8.1 Net cash from / (used in) operating activities (item 1.9)                                                                                                                                                                                                                                                                                                                                                          | (4,757)      |
| 8.2 Cash and cash equivalents at quarter end (item 4.6)                                                                                                                                                                                                                                                                                                                                                                | 2,436        |
| 8.3 Unused finance facilities available at quarter end (item 7.5)                                                                                                                                                                                                                                                                                                                                                      | -            |
| 8.4 Total available funding (item 8.2 + item 8.3)                                                                                                                                                                                                                                                                                                                                                                      | 2,436        |
| 8.5 <b>Estimated quarters of funding available (item 8.4 divided by item 8.1)</b>                                                                                                                                                                                                                                                                                                                                      | 0.5          |
| <i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>                                                                                                                                                                                                     |              |
| 8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:                                                                                                                                                                                                                                                                                                                            |              |
| 8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?                                                                                                                                                                                                                                                                      |              |
| Answer: No. Our receipts during Q3 were impacted by delayed payments by customers. Q4 and Q1 have historically been the Company's strongest cash-receipt quarters and have generally recorded the lowest net operating cash outflows, reflecting the billing and collection of several large annual customer renewals during these periods.                                                                            |              |
| 8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?                                                                                                                                                                                                 |              |
| Answer: Tranche 2 of the two-tranche institutional placement announced in March 2026 will raise a further A\$7 million (approximately €4.4 million) in gross proceeds, it remains subject to shareholder approval which is fully expected. Settlement of Tranche 2 will occur following receipt of this approval, which the Company is seeking at its annual general meeting, which is being held on 25 November 2026. |              |

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: Yes. The Company's cash balance at 26 October 2026 is €4.2 million (A\$6.7 million and the Company expects its cash position to be strengthened by the inflow of the A\$7.0 million (approximately €4.4 million) proceeds from Tranche 2 of the Placement, following the AGM on 25 November 2026, and stronger cash receipts during the fourth quarter of 2026 and the first quarter of 2027.

*Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.*

## Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: .....26 October 2026.....

Authorised by: ..... **BY THE BOARD** .....  
 (Name of body or officer authorising release – see note 4)

## Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.